{"transactions":[{"id":854620,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Statutory Stock Option NQ","published_at":"2026-03-09T22:09:38.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":152000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date."}],"balance_after":152000,"derivative":{"exercise_price":10.11,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":152000},"source":{"system":"sec-edgar","filing":"0001104659-26-025365","document":"tm268290-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926025365/tm268290-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-03-03"}},{"id":859551,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-05T11:01:36.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the \"Plan\") vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date."}],"balance_after":4000,"derivative":{"exercise_price":0,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-26-023715","document":"tm268076-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023715/tm268076-1_4seq1.xml","form_type":"4"}},{"id":859550,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T11:01:36.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":11378,"price":9.49,"value":107977.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting."}],"balance_after":90067,"source":{"system":"sec-edgar","filing":"0001104659-26-023715","document":"tm268076-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023715/tm268076-1_4seq1.xml","form_type":"4"}},{"id":859549,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-05T11:01:36.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101445,"source":{"system":"sec-edgar","filing":"0001104659-26-023715","document":"tm268076-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023715/tm268076-1_4seq1.xml","form_type":"4"}},{"id":870548,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Non-Statutory Stock Opotion NQ","published_at":"2026-03-04T02:33:22.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":152000,"price":9.09,"value":1381680.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date."}],"balance_after":152000,"derivative":{"exercise_price":9.09,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":152000},"source":{"system":"sec-edgar","filing":"0001104659-26-023069","document":"tm267953-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023069/tm267953-1_4seq1.xml","form_type":"4"}},{"id":870547,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T02:33:22.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":101000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date."}],"balance_after":101000,"derivative":{"exercise_price":0,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0001104659-26-023069","document":"tm267953-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023069/tm267953-1_4seq1.xml","form_type":"4"}},{"id":870546,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T02:33:22.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the \"Plan\") vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date."}],"balance_after":4000,"derivative":{"exercise_price":0,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-26-023069","document":"tm267953-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023069/tm267953-1_4seq1.xml","form_type":"4"}},{"id":870545,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:33:22.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1214,"price":10.14,"value":12309.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting."}],"balance_after":63945,"source":{"system":"sec-edgar","filing":"0001104659-26-023069","document":"tm267953-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023069/tm267953-1_4seq1.xml","form_type":"4"}},{"id":870544,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:33:22.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":65159,"source":{"system":"sec-edgar","filing":"0001104659-26-023069","document":"tm267953-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926023069/tm267953-1_4seq1.xml","form_type":"4"}},{"id":970051,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-15T21:01:11.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":false,"shares":41899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date."}],"balance_after":41899,"derivative":{"exercise_price":0,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":41899},"source":{"system":"sec-edgar","filing":"0001104659-25-121103","document":"tm2533544-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925121103/tm2533544-1_4seq1.xml","form_type":"4"}},{"id":970050,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-15T21:01:11.000Z","date":"2025-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12713,"price":6.69,"value":85049.97,"ownership":{"direct":true},"balance_after":61159,"source":{"system":"sec-edgar","filing":"0001104659-25-121103","document":"tm2533544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925121103/tm2533544-1_4seq1.xml","form_type":"4"}},{"id":970049,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-15T21:01:11.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":true,"shares":41899,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":73972,"source":{"system":"sec-edgar","filing":"0001104659-25-121103","document":"tm2533544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925121103/tm2533544-1_4seq1.xml","form_type":"4"}},{"id":1224138,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"2025 Restricted Stock Units RSU","published_at":"2025-03-05T22:07:27.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":0,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001593968-25-000306","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000306/primary_01.xml","form_type":"4"}},{"id":1224137,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"2025 Non-statutory Stock Option NQ","published_at":"2025-03-05T22:07:27.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":169000,"price":7.87,"value":1330030.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date."}],"balance_after":169000,"derivative":{"exercise_price":7.87,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":169000},"source":{"system":"sec-edgar","filing":"0001593968-25-000306","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000306/primary_01.xml","form_type":"4"}},{"id":1231756,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T23:46:08.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":0,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001593968-25-000288","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000288/primary_01.xml","form_type":"4"}},{"id":1231755,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-04T23:46:08.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1214,"price":8.33,"value":10112.62,"ownership":{"direct":true},"balance_after":31973,"source":{"system":"sec-edgar","filing":"0001593968-25-000288","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000288/primary_01.xml","form_type":"4"}},{"id":1231754,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-04T23:46:08.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33187,"source":{"system":"sec-edgar","filing":"0001593968-25-000288","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000288/primary_01.xml","form_type":"4"}},{"id":1333041,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-13T22:24:48.000Z","date":"2024-12-11","kind":"exercise","planned":false,"acquired":false,"shares":41900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date."}],"balance_after":83798,"derivative":{"exercise_price":0,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":41900},"source":{"system":"sec-edgar","filing":"0001593968-24-001472","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824001472/primary_01.xml","form_type":"4"}},{"id":1333040,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-12-13T22:24:48.000Z","date":"2024-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12713,"price":8.82,"value":112128.66,"ownership":{"direct":true},"balance_after":29187,"source":{"system":"sec-edgar","filing":"0001593968-24-001472","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824001472/primary_01.xml","form_type":"4"}},{"id":1333039,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"officer":true,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-12-13T22:24:48.000Z","date":"2024-12-11","kind":"exercise","planned":false,"acquired":true,"shares":41900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41900,"source":{"system":"sec-edgar","filing":"0001593968-24-001472","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824001472/primary_01.xml","form_type":"4"}},{"id":1561108,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CLO & Corporate Secretary"}}],"security":"Restricted Stock Units","published_at":"2024-03-26T23:00:09.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-24-039161","document":"tm249879-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924039161/tm249879-1_4seq1.xml","form_type":"4"}},{"id":1713035,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-13T22:00:21.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":125698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date."}],"balance_after":125698,"derivative":{"underlying":"Common Stock","underlying_shares":125698},"source":{"system":"sec-edgar","filing":"0001209191-23-058519","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123058519/doc4.xml","form_type":"4"}},{"id":1713034,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-12-13T22:00:21.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":144694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), will vest on the first anniversary of the December 11, 2023 grant date (the \"Grant Date\"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date."}],"balance_after":144694,"derivative":{"exercise_price":5.57,"exercise_date":"2024-12-11","expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":144694},"source":{"system":"sec-edgar","filing":"0001209191-23-058519","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123058519/doc4.xml","form_type":"4"}},{"id":2225275,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:12:57.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":78129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":78129},"source":{"system":"sec-edgar","filing":"0000899243-22-023430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000089924322023430/doc4.xml","form_type":"4"}},{"id":2225274,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:12:57.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":128657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary Shares","underlying_shares":128657},"source":{"system":"sec-edgar","filing":"0000899243-22-023430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000089924322023430/doc4.xml","form_type":"4"}},{"id":2225273,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T18:12:57.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":39581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":18.15,"exercise_date":"2019-02-01","expiration_date":"2028-02-01","underlying":"Ordinary Shares","underlying_shares":39581},"source":{"system":"sec-edgar","filing":"0000899243-22-023430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000089924322023430/doc4.xml","form_type":"4"}},{"id":2225272,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2022-06-21T18:12:57.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":32011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-023430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000089924322023430/doc4.xml","form_type":"4"}},{"id":2937709,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-18T07:39:24.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":15291,"price":0.45,"value":6880.95,"ownership":{"direct":true},"balance_after":32011,"source":{"system":"sec-edgar","filing":"0000950138-20-000533","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013820000533/edgar.xml","form_type":"4"}},{"id":3182949,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-03T16:19:57.000Z","date":"2020-04-02","kind":"tax_withholding","acquired":false,"shares":2110,"price":1.8,"value":3798.0,"ownership":{"direct":true},"balance_after":47302,"source":{"system":"sec-edgar","filing":"0000950138-20-000198","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013820000198/edgar.xml","form_type":"4"}},{"id":3182948,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-03T16:19:57.000Z","date":"2020-04-01","kind":"tax_withholding","acquired":false,"shares":1462,"price":1.93,"value":2821.66,"ownership":{"direct":true},"balance_after":49412,"source":{"system":"sec-edgar","filing":"0000950138-20-000198","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013820000198/edgar.xml","form_type":"4"}},{"id":3291351,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-04T16:06:56.000Z","date":"2020-02-01","kind":"tax_withholding","acquired":false,"shares":1252,"price":4.59,"value":5746.68,"ownership":{"direct":true},"balance_after":50874,"source":{"system":"sec-edgar","filing":"0000950138-20-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013820000049/edgar.xml","form_type":"4"}},{"id":3561273,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-05T16:14:21.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":78129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amended Form 4 is being filed to correct a typographical error in the exercise price of the options which was previously reported as $22.62."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":78129,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":78129},"source":{"system":"sec-edgar","filing":"0000950138-19-000237","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013819000237/edgar.xml","form_type":"4/A","original_submission_date":"2019-04-03"}},{"id":3564418,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-03T18:04:20.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":78129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":78129,"derivative":{"exercise_price":22.62,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":78129},"source":{"system":"sec-edgar","filing":"0000950138-19-000229","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013819000229/edgar.xml","form_type":"4"}},{"id":3564417,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-04-03T18:04:20.000Z","date":"2019-04-02","kind":"tax_withholding","acquired":false,"shares":2110,"price":22.8,"value":48108.0,"ownership":{"direct":true},"balance_after":52126,"source":{"system":"sec-edgar","filing":"0000950138-19-000229","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013819000229/edgar.xml","form_type":"4"}},{"id":3564416,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-04-03T18:04:20.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":17071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020."}],"balance_after":54236,"source":{"system":"sec-edgar","filing":"0000950138-19-000229","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013819000229/edgar.xml","form_type":"4"}},{"id":3674027,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Ordinary Shares","published_at":"2019-02-05T07:59:06.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":1248,"price":22.34,"value":27880.32,"ownership":{"direct":true},"balance_after":37165,"source":{"system":"sec-edgar","filing":"0000950138-19-000060","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013819000060/edgar.xml","form_type":"4"}},{"id":3969668,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2018-04-04T18:13:47.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":128657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 2, 2019."}],"balance_after":128657,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary Shares","underlying_shares":128657},"source":{"system":"sec-edgar","filing":"0000950138-18-000315","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013818000315/edgar.xml","form_type":"4"}},{"id":3969667,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-04-04T18:13:47.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":24638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019."}],"balance_after":38413,"source":{"system":"sec-edgar","filing":"0000950138-18-000315","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013818000315/edgar.xml","form_type":"4"}},{"id":4076131,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2018-02-05T17:02:49.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":39581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning February 1, 2019."}],"balance_after":39581,"derivative":{"exercise_price":18.15,"exercise_date":"2019-02-01","expiration_date":"2028-02-01","underlying":"Ordinary Shares","underlying_shares":39581},"source":{"system":"sec-edgar","filing":"0000950138-18-000113","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013818000113/edgar.xml","form_type":"4"}},{"id":4076130,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Ordinary Shares","published_at":"2018-02-05T17:02:49.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":13775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning February 1, 2019."}],"balance_after":13775,"source":{"system":"sec-edgar","filing":"0000950138-18-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415297/000095013818000113/edgar.xml","form_type":"4"}},{"id":4106072,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option","published_at":"2018-01-05T16:19:46.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":270000,"price":2.24,"value":604800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant."}],"balance_after":270000,"derivative":{"exercise_price":2.24,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001179110-18-000586","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911018000586/edgar.xml","form_type":"4"}},{"id":4496990,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":62129,"kind":"person","name":"Casey Mark J","position":1,"cik":"0001415297","reported_name":"Casey Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option","published_at":"2017-01-06T16:24:02.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted under the Company's 2013 Stock Incentive Plan.  The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant."}],"balance_after":185000,"derivative":{"exercise_price":1.59,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001179110-17-000645","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911017000645/edgar.xml","form_type":"4"}}]}